1. Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Current Approach to Ovarian Cancer

5. Case: Lauren

6. Case (cont)

7. Genetic Testing of Ovarian Cancer

8. Frequency of Ovarian Cancer Mutations

9. Points of Emphasis: Family History

10. If Family History Is Unknown

11. Genetic Counseling

12. Germline Testing

13. Psychosocial Considerations

14. Case (cont)

15. BRCA1 vs BRCA2: Ovarian Cancer

16. BRCA1 vs BRCA2: Breast Cancer

17. Risk of Malignancy in BRCA2-Mutated Patients

18. Testing Family Members

19. Pancreatic Cancer Screening for Patients With BRCA2 Mutations

20. Managing Breast Cancer Risk in Patients With Advanced Ovarian Cancer

21. Newly Diagnosed Ovarian Cancer

22. Case (cont)

23. What if Lauren Had Tested Negative for BRCA1 or BRCA2?

24. Germline vs Somatic Mutations

25. Tumor Testing: Institutional Issues

26. PARP Inhibitors

27. PARP Inhibitors: Safety

28. Setting Patient Expectations

29. Key Takeaways

30. Abbreviations